Viracta Therapeutics to Present at H.C. Wainwright Global Conference
03 Sep 2024 //
GLOBENEWSWIRE
Viracta Announces Positive Data From Phase 2 Trial And Regulatory Progress
14 Aug 2024 //
GLOBENEWSWIRE
Viracta Therapeutics Reports Q2 2024 Financial Results And Business Update
14 Aug 2024 //
GLOBENEWSWIRE
Viracta Lays Off 23% In Slimdown For Lymphoma Race To Finish Line
14 Aug 2024 //
FIERCE BIOTECH
Viracta Therapeutics Announces New Employment Inducement Grants
17 May 2024 //
GLOBENEWSWIRE
Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer
14 May 2024 //
GLOBENEWSWIRE
Viracta Therapeutics Q1 2024 Financials And Business Update
09 May 2024 //
GLOBENEWSWIRE
Viracta Therapeutics to Present at RBC Healthcare Conference
06 May 2024 //
GLOBENEWSWIRE
Viracta Positive Nana-val NAVAL-1 EBV+ PTCL Topline Results
15 Apr 2024 //
GLOBENEWSWIRE
Viracta to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial
01 Apr 2024 //
GLOBENEWSWIRE
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
07 Mar 2024 //
GLOBENEWSWIRE
Viracta Announces Completion of Enrollment into NAVAL-1 Trial
29 Feb 2024 //
GLOBENEWSWIRE
Viracta to Present at the Oppenheimer 34th Annual Life Sciences Conference
06 Feb 2024 //
GLOBENEWSWIRE
Viracta Therapeutics Provides Clinical Update and Outlook for 2024
04 Jan 2024 //
GLOBENEWSWIRE
Viracta Announces Orphan Drug Designation Granted by FDA to Nana-val
12 Dec 2023 //
GLOBENEWSWIRE
Viracta Announces Data from Phase 1b/2 Clinical Trial of Nana-val in Patients
04 Dec 2023 //
GLOBENEWSWIRE
Viracta Therapeutics Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Viracta Therapeutics to Present at Upcoming Investor Conferences
07 Nov 2023 //
GLOBENEWSWIRE
Viracta to Host R&D Day Highlighting Nana-val in EBV-Associated Cancers
04 Oct 2023 //
GLOBENEWSWIRE
Viracta Therapeutics to Host R&D Day on October 4, 2023
05 Sep 2023 //
GLOBENEWSWIRE
Viracta Therapeutics Announces New Employment Inducement Grant
18 Aug 2023 //
GLOBENEWSWIRE
Viracta Therapeutics Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
Viracta Therapeutics Appoints Darrel P. Cohen as Chief Medical Officer
07 Aug 2023 //
GLOBENEWSWIRE
Viracta Therapeutics€™ Pivotal NAVAL-1 Trial Achieves Efficacy Threshold
28 Jun 2023 //
GLOBENEWSWIRE
Viracta Therapeutics to Present at the Jefferies Healthcare Conference
31 May 2023 //
GLOBENEWSWIRE
Viracta Therapeutics Reports 1Q 2023 FYR and Provides Clinical Program Updates
08 May 2023 //
GLOBENEWSWIRE
Viracta Therapeutics Announces Departure of Chief Medical Officer
02 May 2023 //
GLOBENEWSWIRE
Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days
19 Apr 2023 //
GLOBENEWSWIRE
Viracta Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
13 Mar 2023 //
GLOBENEWSWIRE
Viracta to Present at the 2023 SVB Securities Global Biopharma Conference
07 Feb 2023 //
GLOBENEWSWIRE
Viracta Therapeutics Announces Orphan Drug Designation Granted by EC to Nana-val
19 Jan 2023 //
GLOBENEWSWIRE
Viracta Announces First Clinical Response in EBV+ Solid Tumor Setting
08 Jan 2023 //
GLOBENEWSWIRE
Viracta Therapeutics Announces Preliminary Dose-Ranging Data from Ph 1b/2 Trial
30 Nov 2022 //
GLOBENEWSWIRE
Viracta Therapeutics Announces New Employment Inducement Grant
21 Nov 2022 //
GLOBENEWSWIRE
Viracta Therapeutics to Present at Upcoming Investor Conferences
02 Nov 2022 //
GLOBENEWSWIRE
Viracta Therapeutics Announces Chief Executive Officer Leadership Succession
19 Sep 2022 //
PRNEWSWIRE
Viracta Therapeutics Announces New Employment Inducement Grant
19 Sep 2022 //
GLOBENEWSWIRE
Viracta Announces Orphan Drug Designation Granted by the European Commission
07 Sep 2022 //
PRNEWSWIRE
Viracta`s CSO, Dr. Ayman Elguindy, Elected to Governing Board of EBV Association
16 Aug 2022 //
PRNEWSWIRE
Viracta Tx Reports Second Quarter 2022 Financial Results and Recent Updates
09 Aug 2022 //
PRNEWSWIRE
Viracta Therapeutics Provides an Update on the Phase 1b/2 Trial of Nana-val
02 Jun 2022 //
PRNEWSWIRE
Viracta Therapeutics to Present at the Jefferies Healthcare Conference
01 Jun 2022 //
PRNEWSWIRE
Viracta Therapeutics Announces New Employment Inducement Grant
13 May 2022 //
PRNEWSWIRE
Viracta Therapeutics to Present at Upcoming May Investor Conferences
11 May 2022 //
PRNEWSWIRE
Viracta Therapeutics Reports First Quarter 2022 Financial Results
10 May 2022 //
PRNEWSWIRE
Viracta to Host Key Opinion Leader Webinar on Nana-val
20 Apr 2022 //
PRNEWSWIRE
Viracta Tx to Present at 21st Annual Needham Virtual Healthcare Conference
07 Apr 2022 //
PRNEWSWIRE
Viracta Tx says New Employment Inducement Grant
18 Mar 2022 //
PRNEWSWIRE
Viracta Announces Final Phase 1b/2 Data Showing Efficacy for Nana-val
13 Dec 2021 //
PRNEWSWIRE
Viracta Therapeutics Announces Orphan Drug Designation Granted
29 Nov 2021 //
PRNEWSWIRE
Viracta Therapeutics Announces Upcoming Oral and Poster PresentationASH
04 Nov 2021 //
PRNEWSWIRE
Viracta reacquires exclusive rights for oral combination therapy in China
23 Aug 2021 //
SEEKINGALPFA
Viracta Clearance of IND for Phase 1b/2 Epstein-Barr Virus-Positive Tumors
21 Jul 2021 //
PRNEWSWIRE
Viracta Therapeutics Announces the Appointment of Ayman El-Guindy
07 Jul 2021 //
PR NEWSWIRE
Viracta Therapeutics Announces the Appointment of Ayman El-Guindy
07 Jul 2021 //
PR NEWSWIRE
Viracta Reports Q1 2021 Financial Results & Provides Clinical Updates
12 May 2021 //
PRNEWSWIRE
Viracta and XOMA Announce Multi-License Milestone and Royalty
23 Mar 2021 //
PRNEWSWIRE
Viracta and XOMA Announce Multi-License Milestone and Royalty Monetization
23 Mar 2021 //
BIOSPACE
Viracta Strengthens Company Leadership with New Appointments
04 Mar 2021 //
PRNEWSWIRE